

SPEAKER: Who is the patient who is the most eligible for this is the patient post-ACS. Because ACS patients have a much higher risk of recurrent ACS than patients who never had ACS, although they have symptomatic coronary disease. I think symptomatic coronary disease, without MIs or ACS, is a very low-risk population in the first place.

Patients who have developed an ACS, they have a thrombotic tendency. Of course, they should have strong antithrombotic therapy. But on top of that, they should also have the best lipid-lowering strategies.